{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T14:33:57Z","timestamp":1792679637329,"version":"4.5.0"},"reference-count":71,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,12,4]],"date-time":"2017-12-04T00:00:00Z","timestamp":1512345600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2017,12,4]],"date-time":"2017-12-04T00:00:00Z","timestamp":1512345600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Recombinant vaccine strain-derived measles virus (MV) is clinically tested both as vaccine platform to protect against other pathogens and as oncolytic virus for tumor treatment. To investigate the potential synergism in anti-tumoral efficacy of oncolytic and vaccine properties, we chose Ovalbumin and an ideal tumor antigen, claudin-6, for pre-clinical proof of concept. To enhance immunogenicity, both antigens were presented by retroviral virus-like particle produced <jats:italic>in situ<\/jats:italic> during MV-infection. All recombinant MV revealed normal growths, genetic stability, and proper expression and presentation of both antigens. Potent antigen-specific humoral and cellular immunity were found in immunized MV-susceptible IFNAR<jats:sup>\u2212\/\u2212<\/jats:sup>-CD46Ge mice. These immune responses significantly inhibited metastasis formation or increased therapeutic efficacy compared to control MV in respective novel <jats:italic>in vivo<\/jats:italic> tumor models using syngeneic B16-hCD46\/mCLDN6 murine melanoma cells. These data indicate the potential of MV to trigger selected tumor\u00a0antigen-specific immune responses on top of direct tumor lysis for enhanced efficacy.<\/jats:p>","DOI":"10.1038\/s41598-017-16928-8","type":"journal-article","created":{"date-parts":[[2017,11,28]],"date-time":"2017-11-28T14:55:53Z","timestamp":1511880953000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Antigen-specific oncolytic MV-based tumor vaccines through presentation of selected tumor-associated antigens on infected cells or virus-like particles"],"prefix":"10.1038","volume":"7","author":[{"given":"Stefan","family":"Hutzler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Erbar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A.","family":"Jabulowsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan R. H.","family":"Hanauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00fcrgen H.","family":"Schnotz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim","family":"Beissert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bianca S.","family":"Bodmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Regina","family":"Eberle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaus","family":"Boller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thorsten","family":"Klamp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ugur","family":"Sahin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael D.","family":"M\u00fchlebach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,12,4]]},"reference":[{"key":"16928_CR1","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1038\/nature14426","volume":"520","author":"S Kreiter","year":"2015","unstructured":"Kreiter, S. et al. Mutant MHC class II epitopes drive therapeutic immune responses to cancer. Nature \n                           520, 692\u2013696 (2015).","journal-title":"Nature"},{"key":"16928_CR2","doi-asserted-by":"crossref","unstructured":"The FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. The New England journal of medicine \n                           356, 1915\u20131927 (2007).","DOI":"10.1056\/NEJMoa061741"},{"key":"16928_CR3","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.immuni.2013.07.004","volume":"39","author":"K Palucka","year":"2013","unstructured":"Palucka, K. & Banchereau, J. Dendritic-cell-based therapeutic cancer vaccines. Immunity \n                           39, 38\u201348 (2013).","journal-title":"Immunity"},{"key":"16928_CR4","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1056\/NEJMoa1001294","volume":"363","author":"PW Kantoff","year":"2010","unstructured":"Kantoff, P. W. et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. The New England journal of medicine \n                           363, 411\u2013422 (2010).","journal-title":"The New England journal of medicine"},{"key":"16928_CR5","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1038\/nrd4278","volume":"13","author":"U Sahin","year":"2014","unstructured":"Sahin, U., Kariko, K. & Tureci, O. mRNA-based therapeutics\u2013developing a new class of drugs. Nature reviews. Drug discovery \n                           13, 759\u2013780 (2014).","journal-title":"Nature reviews. Drug discovery"},{"key":"16928_CR6","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1038\/nrmicro3140","volume":"12","author":"TS Miest","year":"2014","unstructured":"Miest, T. S. & Cattaneo, R. New viruses for cancer therapy: meeting clinical needs. Nature reviews. Microbiology \n                           12, 23\u201334 (2014).","journal-title":"Nature reviews. Microbiology"},{"key":"16928_CR7","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1038\/nbt.2287","volume":"30","author":"SJ Russell","year":"2012","unstructured":"Russell, S. J., Peng, K.-W. & Bell, J. C. Oncolytic virotherapy. Nature biotechnology \n                           30, 658\u2013670 (2012).","journal-title":"Nature biotechnology"},{"key":"16928_CR8","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1007\/s40265-015-0522-7","volume":"76","author":"SL Greig","year":"2016","unstructured":"Greig, S. L. Talimogene Laherparepvec: First Global Approval. Drugs \n                           76, 147\u2013154 (2016).","journal-title":"Drugs"},{"key":"16928_CR9","doi-asserted-by":"publisher","first-page":"2780","DOI":"10.1200\/JCO.2014.58.3377","volume":"33","author":"RHI Andtbacka","year":"2015","unstructured":"Andtbacka, R. H. I. et al. Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma. Journal of clinical oncology: official journal of the American Society of Clinical Oncology \n                           33, 2780\u20132788 (2015).","journal-title":"Journal of clinical oncology: official journal of the American Society of Clinical Oncology"},{"key":"16928_CR10","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1089\/hum.2012.205","volume":"24","author":"C Grossardt","year":"2013","unstructured":"Grossardt, C. et al. Granulocyte-macrophage colony-stimulating factor-armed oncolytic measles virus is an effective therapeutic cancer vaccine. Human gene therapy \n                           24, 644\u2013654 (2013).","journal-title":"Human gene therapy"},{"key":"16928_CR11","first-page":"6463","volume":"63","author":"D Grote","year":"2003","unstructured":"Grote, D., Cattaneo, R. & Fielding, A. K. Neutrophils contribute to the measles virus-induced antitumor effect: enhancement by granulocyte macrophage colony-stimulating factor expression. Cancer research \n                           63, 6463\u20136468 (2003).","journal-title":"Cancer research"},{"key":"16928_CR12","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1038\/mt.2014.160","volume":"22","author":"CE Engeland","year":"2014","unstructured":"Engeland, C. E. et al. CTLA-4 and PD-L1 checkpoint blockade enhances oncolytic measles virus therapy. Molecular therapy: the journal of the American Society of Gene Therapy \n                           22, 1949\u20131959 (2014).","journal-title":"Molecular therapy: the journal of the American Society of Gene Therapy"},{"key":"16928_CR13","doi-asserted-by":"publisher","first-page":"1814","DOI":"10.1038\/mt.2009.154","volume":"17","author":"BW Bridle","year":"2009","unstructured":"Bridle, B. W. et al. Vesicular stomatitis virus as a novel cancer vaccine vector to prime antitumor immunity amenable to rapid boosting with adenovirus. Molecular therapy: the journal of the American Society of Gene Therapy \n                           17, 1814\u20131821 (2009).","journal-title":"Molecular therapy: the journal of the American Society of Gene Therapy"},{"key":"16928_CR14","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1038\/mt.2013.249","volume":"22","author":"JG Pol","year":"2014","unstructured":"Pol, J. G. et al. Maraba virus as a potent oncolytic vaccine vector. Molecular therapy: the journal of the American Society of Gene Therapy \n                           22, 420\u2013429 (2014).","journal-title":"Molecular therapy: the journal of the American Society of Gene Therapy"},{"key":"16928_CR15","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1086\/426824","volume":"191","author":"P Despres","year":"2005","unstructured":"Despres, P. et al. Live measles vaccine expressing the secreted form of the West Nile virus envelope glycoprotein protects against West Nile virus encephalitis. The Journal of infectious diseases \n                           191, 207\u2013214 (2005).","journal-title":"The Journal of infectious diseases"},{"key":"16928_CR16","doi-asserted-by":"publisher","first-page":"11654","DOI":"10.1128\/JVI.01815-15","volume":"89","author":"AH Malczyk","year":"2015","unstructured":"Malczyk, A. H. et al. A Highly Immunogenic and Protective Middle East Respiratory Syndrome Coronavirus Vaccine Based on a Recombinant Measles Virus Vaccine Platform. Journal of virology \n                           89, 11654\u201311667 (2015).","journal-title":"Journal of virology"},{"key":"16928_CR17","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/S1473-3099(15)70043-5","volume":"15","author":"K Ramsauer","year":"2015","unstructured":"Ramsauer, K. et al. Immunogenicity, safety, and tolerability of a recombinant measles-virus-based chikungunya vaccine: a randomised, double-blind, placebo-controlled, active-comparator, first-in-man trial. The Lancet. Infectious diseases \n                           15, 519\u2013527 (2015).","journal-title":"The Lancet. Infectious diseases"},{"key":"16928_CR18","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1002\/dvdy.1174","volume":"222","author":"K Turksen","year":"2001","unstructured":"Turksen, K. & Troy, T. C. Claudin-6: a novel tight junction molecule is developmentally regulated in mouse embryonic epithelium. Developmental dynamics: an official publication of the American Association of Anatomists \n                           222, 292\u2013300 (2001).","journal-title":"Developmental dynamics: an official publication of the American Association of Anatomists"},{"key":"16928_CR19","doi-asserted-by":"publisher","first-page":"F1132","DOI":"10.1152\/ajprenal.00063.2006","volume":"291","author":"G Abuazza","year":"2006","unstructured":"Abuazza, G. et al. Claudins 6, 9, and 13 are developmentally expressed renal tight junction proteins. American journal of physiology. Renal physiology \n                           291, F1132\u201341 (2006).","journal-title":"American journal of physiology. Renal physiology"},{"key":"16928_CR20","first-page":"1146","volume":"64","author":"T D\u2019Souza","year":"2009","unstructured":"D\u2019Souza, T., Sherman-Baust, C. A., Poosala, S., Mullin, J. M. & Morin, P. J. Age-related changes of claudin expression in mouse liver, kidney, and pancreas. The journals of gerontology. Series A, Biological sciences and medical sciences \n                           64, 1146\u20131153 (2009).","journal-title":"J. Age-related changes of claudin expression in mouse liver, kidney, and pancreas. The journals of gerontology. Series A, Biological sciences and medical sciences"},{"key":"16928_CR21","doi-asserted-by":"publisher","first-page":"2206","DOI":"10.1002\/ijc.28857","volume":"135","author":"P Micke","year":"2014","unstructured":"Micke, P. et al. Aberrantly activated claudin 6 and 18.2 as potential therapy targets in non-small-cell lung cancer. International journal of cancer \n                           135, 2206\u20132214 (2014).","journal-title":"International journal of cancer"},{"key":"16928_CR22","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1007\/s12029-009-9110-y","volume":"41","author":"E Rend\u00f3n-Huerta","year":"2010","unstructured":"Rend\u00f3n-Huerta, E. et al. Distribution and expression pattern of claudins 6, 7, and 9 in diffuse- and intestinal-type gastric adenocarcinomas. Journal of gastrointestinal cancer \n                           41, 52\u201359 (2010).","journal-title":"Journal of gastrointestinal cancer"},{"key":"16928_CR23","doi-asserted-by":"publisher","first-page":"e1091555","DOI":"10.1080\/2162402X.2015.1091555","volume":"5","author":"CR Stadler","year":"2016","unstructured":"Stadler, C. R. et al. Characterization of the first-in-class T-cell-engaging bispecific single-chain antibody for targeted immunotherapy of solid tumors expressing the oncofetal protein claudin 6. Oncoimmunology \n                           5, e1091555 (2016).","journal-title":"Oncoimmunology"},{"key":"16928_CR24","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1111\/j.1365-2559.2012.04314.x","volume":"61","author":"T Ushiku","year":"2012","unstructured":"Ushiku, T., Shinozaki-Ushiku, A., Maeda, D., Morita, S. & Fukayama, M. Distinct expression pattern of claudin-6, a primitive phenotypic tight junction molecule, in germ cell tumours and visceral carcinomas. Histopathology \n                           61, 1043\u20131056 (2012).","journal-title":"Histopathology"},{"key":"16928_CR25","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms2992","volume":"4","author":"U Ben-David","year":"2013","unstructured":"Ben-David, U., Nudel, N. & Benvenisty, N. Immunologic and chemical targeting of the tight-junction protein Claudin-6 eliminates tumorigenic human pluripotent stem cells. Nature communications \n                           4, 1992 (2013).","journal-title":"Nature communications"},{"key":"16928_CR26","doi-asserted-by":"crossref","first-page":"5537","DOI":"10.1200\/jco.2015.33.15_suppl.5537","volume":"33","author":"U Sahin","year":"2015","unstructured":"Sahin, U. et al. First-in-human phase I\/II dose-escalation study of IMAB027 in patients with recurrent advanced ovarian cancer (OVAR). Preliminary data of phase I part. Journal of Clinical Oncology \n                           33, 5537 (2015).","journal-title":"Journal of Clinical Oncology"},{"key":"16928_CR27","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1016\/j.mayocp.2014.04.003","volume":"89","author":"SJ Russell","year":"2014","unstructured":"Russell, S. J. et al. Remission of disseminated cancer after systemic oncolytic virotherapy. Mayo Clinic proceedings \n                           89, 926\u2013933 (2014).","journal-title":"Mayo Clinic proceedings"},{"key":"16928_CR28","unstructured":"Griffin, D. E. In Wiley Encyclopedia of Molecular Medicine (John Wiley & Sons, Inc, Hoboken, NJ, USA, 2002)."},{"key":"16928_CR29","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1016\/S0264-410X(01)00384-X","volume":"20","author":"MR Hilleman","year":"2001","unstructured":"Hilleman, M. R. Current overview of the pathogenesis and prophylaxis of measles with focus on practical implications. Vaccine \n                           20, 651\u2013665 (2001).","journal-title":"Vaccine"},{"key":"16928_CR30","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1016\/S0264-410X(00)00175-4","volume":"19","author":"J Mossong","year":"2000","unstructured":"Mossong, J., O\u2019Callaghan, C. J. & Ratnam, S. Modelling antibody response to measles vaccine and subsequent waning of immunity in a low exposure population. Vaccine \n                           19, 523\u2013529 (2000).","journal-title":"Vaccine"},{"key":"16928_CR31","doi-asserted-by":"publisher","first-page":"2580","DOI":"10.1016\/S0264-410X(03)00053-7","volume":"21","author":"B Rager-Zisman","year":"2003","unstructured":"Rager-Zisman, B. et al. The effect of measles-mumps-rubella (MMR) immunization on the immune responses of previously immunized primary school children. Vaccine \n                           21, 2580\u20132588 (2003).","journal-title":"Vaccine"},{"key":"16928_CR32","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1002\/jmv.10390","volume":"70","author":"RM Wong-Chew","year":"2003","unstructured":"Wong-Chew, R. M., Beeler, J. A., Audet, S. & Santos, J. I. Cellular and humoral immune responses to measles in immune adults re-immunized with measles vaccine. Journal of medical virology \n                           70, 276\u2013280 (2003).","journal-title":"Journal of medical virology"},{"key":"16928_CR33","doi-asserted-by":"crossref","unstructured":"M\u00fchlebach, M. D. Vaccine platform recombinant measles virus. Virus genes \n                           53, 733\u2013740\u00a0(2017).","DOI":"10.1007\/s11262-017-1486-3"},{"key":"16928_CR34","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1158\/0008-5472.CAN-10-2292","volume":"71","author":"T Klamp","year":"2011","unstructured":"Klamp, T. et al. Highly specific auto-antibodies against claudin-18 isoform 2 induced by a chimeric HBcAg virus-like particle vaccine kill tumor cells and inhibit the growth of lung metastases. Cancer research \n                           71, 516\u2013527 (2011).","journal-title":"Cancer research"},{"key":"16928_CR35","doi-asserted-by":"crossref","unstructured":"Bach, P. et al. Vaccination with Abeta-displaying virus-like particles reduces soluble and insoluble cerebral Abeta and lowers plaque burden in APP transgenic mice. Journal of immunology (Baltimore, Md.: 1950) \n                           182, 7613\u20137624 (2009).","DOI":"10.4049\/jimmunol.0803366"},{"key":"16928_CR36","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3389\/fonc.2017.00114","volume":"7","author":"DE Meyers","year":"2017","unstructured":"Meyers, D. E., Wang, A. A., Thirukkumaran, C. M. & Morris, D. G. Current Immunotherapeutic Strategies to Enhance Oncolytic Virotherapy. Front. Oncol. \n                           7, 7 (2017).","journal-title":"Front. Oncol."},{"key":"16928_CR37","doi-asserted-by":"publisher","first-page":"e1000610","DOI":"10.1371\/journal.pgen.1000610","volume":"5","author":"Y Nakano","year":"2009","unstructured":"Nakano, Y. et al. A claudin-9-based ion permeability barrier is essential for hearing. PLoS genetics \n                           5, e1000610 (2009).","journal-title":"PLoS genetics"},{"key":"16928_CR38","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.1128\/JVI.75.4.1594-1600.2001","volume":"75","author":"N Ono","year":"2001","unstructured":"Ono, N., Tatsuo, H., Tanaka, K., Minagawa, H. & Yanagi, Y. V domain of human SLAM (CDw150) is essential for its function as a measles virus receptor. Journal of virology \n                           75, 1594\u20131600 (2001).","journal-title":"Journal of virology"},{"issue":"Pt 1","key":"16928_CR39","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1042\/bj3300163","volume":"330","author":"A Tsujimura","year":"1998","unstructured":"Tsujimura, A. et al. Molecular cloning of a murine homologue of membrane cofactor protein (CD46): preferential expression in testicular germ cells. The Biochemical journal \n                           330(Pt 1), 163\u2013168 (1998).","journal-title":"The Biochemical journal"},{"key":"16928_CR40","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1038\/nature10639","volume":"480","author":"MD Muhlebach","year":"2011","unstructured":"M\u00fchlebach, M. D. et al. Adherens junction protein nectin-4 is the epithelial receptor for measles virus. Nature \n                           480, 530\u2013533 (2011).","journal-title":"Nature"},{"key":"16928_CR41","doi-asserted-by":"publisher","first-page":"2767","DOI":"10.1099\/vir.0.82221-0","volume":"87","author":"Y Yanagi","year":"2006","unstructured":"Yanagi, Y., Takeda, M. & Ohno, S. Measles virus: cellular receptors, tropism and pathogenesis. The Journal of general virology \n                           87, 2767\u20132779 (2006).","journal-title":"The Journal of general virology"},{"key":"16928_CR42","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/j.immuni.2006.08.007","volume":"25","author":"DB Stetson","year":"2006","unstructured":"Stetson, D. B. & Medzhitov, R. Type I interferons in host defense. Immunity \n                           25, 373\u2013381 (2006).","journal-title":"Immunity"},{"key":"16928_CR43","doi-asserted-by":"publisher","first-page":"4919","DOI":"10.1158\/0008-5472.CAN-04-0884","volume":"64","author":"BD Anderson","year":"2004","unstructured":"Anderson, B. D., Nakamura, T., Russell, S. J. & Peng, K.-W. High CD46 receptor density determines preferential killing of tumor cells by oncolytic measles virus. Cancer research \n                           64, 4919\u20134926 (2004).","journal-title":"Cancer research"},{"key":"16928_CR44","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1038\/nature18300","volume":"534","author":"LM Kranz","year":"2016","unstructured":"Kranz, L. M. et al. Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy. Nature \n                           534, 396\u2013401 (2016).","journal-title":"Nature"},{"key":"16928_CR45","doi-asserted-by":"publisher","first-page":"4753","DOI":"10.1158\/0008-5472.CAN-12-0600","volume":"72","author":"DM Rommelfanger","year":"2012","unstructured":"Rommelfanger, D. M. et al. Systemic combination virotherapy for melanoma with tumor antigen-expressing vesicular stomatitis virus and adoptive T-cell transfer. Cancer research \n                           72, 4753\u20134764 (2012).","journal-title":"Cancer research"},{"key":"16928_CR46","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1038\/nm.2390","volume":"17","author":"T Kottke","year":"2011","unstructured":"Kottke, T. et al. Broad antigenic coverage induced by vaccination with virus-based cDNA libraries cures established tumors. Nature medicine \n                           17, 854\u2013859 (2011).","journal-title":"Nature medicine"},{"key":"16928_CR47","volume":"8","author":"L Wang","year":"2013","unstructured":"Wang, L. et al. Clinicopathologic significance of claudin-6, occludin, and matrix metalloproteinases \u22122 expression in ovarian carcinoma. Diagnostic pathology \n                           8, 190 (2013).","journal-title":"Diagnostic pathology"},{"key":"16928_CR48","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.bbrc.2016.06.025","volume":"477","author":"Y Hashimoto","year":"2016","unstructured":"Hashimoto, Y. et al. Generation and characterization of a human-mouse chimeric antibody against the extracellular domain of claudin-1 for cancer therapy using a mouse model. Biochemical and biophysical research communications \n                           477, 91\u201395 (2016).","journal-title":"Biochemical and biophysical research communications"},{"key":"16928_CR49","doi-asserted-by":"publisher","first-page":"4882","DOI":"10.1158\/0008-5472.CAN-07-6265","volume":"68","author":"A Gauvrit","year":"2008","unstructured":"Gauvrit, A. et al. Measles virus induces oncolysis of mesothelioma cells and allows dendritic cells to cross-prime tumor-specific CD8 response. Cancer research \n                           68, 4882\u20134892 (2008).","journal-title":"Cancer research"},{"key":"16928_CR50","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1158\/1078-0432.CCR-12-2733","volume":"19","author":"J-B Guillerme","year":"2013","unstructured":"Guillerme, J.-B. et al. Measles virus vaccine-infected tumor cells induce tumor antigen cross-presentation by human plasmacytoid dendritic cells. Clinical cancer research: an official journal of the American Association for Cancer Research \n                           19, 1147\u20131158 (2013).","journal-title":"Clinical cancer research: an official journal of the American Association for Cancer Research"},{"key":"16928_CR51","first-page":"74","volume":"4","author":"ZS Guo","year":"2014","unstructured":"Guo, Z. S., Liu, Z. & Bartlett, D. L. Oncolytic Immunotherapy: Dying the Right Way is a Key to Eliciting Potent Antitumor Immunity. Front. Oncol. \n                           4, 74 (2014).","journal-title":"Front. Oncol."},{"key":"16928_CR52","doi-asserted-by":"publisher","first-page":"4714","DOI":"10.1128\/JVI.02633-09","volume":"84","author":"RDde Vries","year":"2010","unstructured":"Vries, R. Dde et al. In vivo tropism of attenuated and pathogenic measles virus expressing green fluorescent protein in macaques. Journal of virology \n                           84, 4714\u20134724 (2010).","journal-title":"Journal of virology"},{"key":"16928_CR53","doi-asserted-by":"publisher","first-page":"2192","DOI":"10.1128\/JVI.02924-14","volume":"89","author":"LJ Rennick","year":"2015","unstructured":"Rennick, L. J. et al. Live-attenuated measles virus vaccine targets dendritic cells and macrophages in muscle of nonhuman primates. Journal of virology \n                           89, 2192\u20132200 (2015).","journal-title":"Journal of virology"},{"key":"16928_CR54","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1038\/sj.gt.3301885","volume":"10","author":"BL Liu","year":"2003","unstructured":"Liu, B. L. et al. ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties. Gene therapy \n                           10, 292\u2013303 (2003).","journal-title":"Gene therapy"},{"key":"16928_CR55","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1126\/science.342.6165.1432","volume":"342","author":"J Couzin-Frankel","year":"2013","unstructured":"Couzin-Frankel, J. Breakthrough of the year 2013. Cancer immunotherapy. Science (New York, N.Y.) \n                           342, 1432\u20131433 (2013).","journal-title":"Cancer immunotherapy. Science (New York, N.Y.)"},{"key":"16928_CR56","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa1003466","volume":"363","author":"FS Hodi","year":"2010","unstructured":"Hodi, F. S. et al. Improved survival with ipilimumab in patients with metastatic melanoma. The New England journal of medicine \n                           363, 711\u2013723 (2010).","journal-title":"The New England journal of medicine"},{"key":"16928_CR57","doi-asserted-by":"publisher","first-page":"1734","DOI":"10.1126\/science.271.5256.1734","volume":"271","author":"DR Leach","year":"1996","unstructured":"Leach, D. R., Krummel, M. F. & Allison, J. P. Enhancement of antitumor immunity by CTLA-4 blockade. Science (New York, N.Y.) \n                           271, 1734\u20131736 (1996).","journal-title":"Science (New York, N.Y.)"},{"key":"16928_CR58","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-015-0455-8","volume":"13","author":"A Bertrand","year":"2015","unstructured":"Bertrand, A., Kostine, M., Barnetche, T., Truchetet, M.-E. & Schaeverbeke, T. Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis. BMC medicine \n                           13, 211 (2015).","journal-title":"BMC medicine"},{"key":"16928_CR59","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1038\/mt.2013.16","volume":"21","author":"K Friedrich","year":"2013","unstructured":"Friedrich, K. et al. DARPin-targeting of measles virus: unique bispecificity, effective oncolysis, and enhanced safety. Molecular therapy: the journal of the American Society of Gene Therapy \n                           21, 849\u2013859 (2013).","journal-title":"Molecular therapy: the journal of the American Society of Gene Therapy"},{"key":"16928_CR60","doi-asserted-by":"publisher","first-page":"9044","DOI":"10.1128\/JVI.00844-15","volume":"89","author":"KM Uhlig","year":"2015","unstructured":"Uhlig, K. M. et al. Lentiviral Protein Transfer Vectors Are an Efficient Vaccine Platform and Induce a Strong Antigen-Specific Cytotoxic T Cell Response. Journal of virology \n                           89, 9044\u20139060 (2015).","journal-title":"Journal of virology"},{"key":"16928_CR61","doi-asserted-by":"publisher","first-page":"10597","DOI":"10.1128\/JVI.00923-07","volume":"81","author":"JR del Valle","year":"2007","unstructured":"del Valle, J. R. et al. A vectored measles virus induces hepatitis B surface antigen antibodies while protecting macaques against measles virus challenge. Journal of virology \n                           81, 10597\u201310605 (2007).","journal-title":"Journal of virology"},{"key":"16928_CR62","doi-asserted-by":"publisher","first-page":"5708","DOI":"10.1128\/JVI.02389-05","volume":"80","author":"A Martin","year":"2006","unstructured":"Martin, A., Staeheli, P. & Schneider, U. RNA polymerase II-controlled expression of antigenomic RNA enhances the rescue efficacies of two different members of the Mononegavirales independently of the site of viral genome replication. Journal of virology \n                           80, 5708\u20135715 (2006).","journal-title":"Journal of virology"},{"key":"16928_CR63","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1089\/10430340252898984","volume":"13","author":"C Demaison","year":"2002","unstructured":"Demaison, C. et al. High-level transduction and gene expression in hematopoietic repopulating cells using a human immunodeficiency correction of imunodeficiency virus type 1-based lentiviral vector containing an internal spleen focus forming virus promoter. Human gene therapy \n                           13, 803\u2013813 (2002).","journal-title":"Human gene therapy"},{"key":"16928_CR64","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1038\/nbt0997-871","volume":"15","author":"R Zufferey","year":"1997","unstructured":"Zufferey, R., Nagy, D., Mandel, R. J., Naldini, L. & Trono, D. Multiply attenuated lentiviral vector achieves efficient gene delivery in vivo. Nature biotechnology \n                           15, 871\u2013875 (1997).","journal-title":"Nature biotechnology"},{"key":"16928_CR65","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1038\/gt.2014.25","volume":"21","author":"L Koste","year":"2014","unstructured":"Koste, L. et al. T-cell receptor transfer into human T cells with ecotropic retroviral vectors. Gene therapy \n                           21, 533\u2013538 (2014).","journal-title":"Gene therapy"},{"key":"16928_CR66","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1007\/BF01863914","volume":"162","author":"G K\u00e4rber","year":"1931","unstructured":"K\u00e4rber, G. Beitrag zur kollektiven Behandlung pharmakologischer Reihenversuche. Archiv f. experiment. Pathol. u. Pharmakol \n                           162, 480\u2013483 (1931).","journal-title":"Archiv f. experiment. Pathol. u. Pharmakol"},{"key":"16928_CR67","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1038\/mt.2008.128","volume":"16","author":"S Funke","year":"2008","unstructured":"Funke, S. et al. Targeted Cell Entry of Lentiviral Vectors. Mol Ther \n                           16, 1427\u20131436 (2008).","journal-title":"Mol Ther"},{"key":"16928_CR68","doi-asserted-by":"crossref","first-page":"7420","DOI":"10.1128\/JVI.72.9.7420-7427.1998","volume":"72","author":"B Mrkic","year":"1998","unstructured":"Mrkic, B. et al. Measles virus spread and pathogenesis in genetically modified mice. Journal of virology \n                           72, 7420\u20137427 (1998).","journal-title":"Journal of virology"},{"key":"16928_CR69","doi-asserted-by":"crossref","unstructured":"Overwijk, W. W. & Restifo, N. P. B16 as a mouse model for human melanoma. Current protocols in immunology Chapter 20, Unit20.1 (2001).","DOI":"10.1002\/0471142735.im2001s39"},{"key":"16928_CR70","doi-asserted-by":"publisher","first-page":"e87822","DOI":"10.1371\/journal.pone.0087822","volume":"9","author":"S Schulke","year":"2014","unstructured":"Schulke, S. et al. Prevention of intestinal allergy in mice by rflaA:Ova is associated with enforced antigen processing and TLR5-dependent IL-10 secretion by mDC. PloS one \n                           9, e87822 (2014).","journal-title":"PloS one"},{"key":"16928_CR71","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1002\/ijc.28400","volume":"134","author":"S Woll","year":"2014","unstructured":"Woll, S. et al. Claudin 18.2 is a target for IMAB362 antibody in pancreatic neoplasms. International journal of cancer \n                           134, 731\u2013739 (2014).","journal-title":"International journal of cancer"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-16928-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-16928-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-16928-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,23]],"date-time":"2022-12-23T14:57:59Z","timestamp":1671807479000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-16928-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12,4]]},"references-count":71,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2017,12]]}},"alternative-id":["16928"],"URL":"https:\/\/doi.org\/10.1038\/s41598-017-16928-8","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,12,4]]},"assertion":[{"value":"12 July 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 November 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 December 2017","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"U.S., S.E., R.A.J., and T.K. are employees of BioNTech Corporation (Mainz, Germany). U.S. is inventor on patents related to this study. U.S. is management board member of BioNTech Corporation. All other authors declare no potential conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"16892"}}